4.5 Article

Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer

期刊

GENE THERAPY
卷 17, 期 6, 页码 721-732

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2010.4

关键词

lentiviral TCR gene transfer; multi-functional T-cells; IL15; IL21

资金

  1. Leukaemia Research, Medical Research Council
  2. MRC [G0700149, G9721629, G0900950] Funding Source: UKRI
  3. Medical Research Council [G0900950, G0900950B, G9721629, G9721629B, G0700149] Funding Source: researchfish
  4. Versus Arthritis [18433] Funding Source: researchfish

向作者/读者索取更多资源

T-cell receptor (TCR) gene transfer is an attractive strategy to generate antigen-specific T-cells for adoptive immunotherapy of cancer and chronic viral infection. However, current TCR gene transfer protocols trigger T-cell differentiation into terminally differentiated effector cells, which likely have reduced ability to mediate disease protection in vivo. We have developed a lentiviral gene transfer strategy to generate TCR-transduced human T-cells without promoting T-cell differentiation. We found that a combination of interleukin-15 (IL15) and IL21 facilitated lentiviral TCR gene transfer into non-proliferating T-cells. The transduced T-cells showed redirection of antigen specificity and produced IL2, IFN gamma and TNF alpha in a peptide-dependent manner. A significantly higher proportion of the IL15/IL21-stimulated T-cells were multi-functional and able to simultaneously produce all three cytokines (P<0.01), compared with TCR-transduced T-cells generated by conventional anti-CD3 plus IL2 stimulation, which primarily secreted only one cytokine. Similarly, IL15/IL21 maintained high levels of CD62L and CD28 expression in transduced T-cells, whereas anti-CD3 plus IL2 accelerated the loss of CD62L/CD28 expression. The data demonstrate that the combination of lentiviral TCR gene transfer together with IL15/IL21 stimulation can efficiently redirect the antigen specificity of resting primary human T-cells and generate multi-functional T-cells. Gene Therapy (2010) 17, 721-732; doi: 10.1038/gt.2010.4; published online 18 February 2010

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Correction Biochemistry & Molecular Biology

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome (Aug, 10.1038/s41591-021-01641-x, 2022)

A. Magnani, M. Semeraro, F. Adam, C. Booth, L. Dupre, E. C. Morris, A. Gabrion, C. Roudaut, D. Borgel, A. Toubert, E. Clave, C. Abdo, G. Gorochov, R. Petermann, M. Guiot, M. Miyara, D. Moshous, E. Magrin, A. Denis, F. Suarez, C. Lagresle, A. M. Roche, J. Everett, A. Trinquand, M. Guisset, J. Xu Bayford, S. Hacein-Bey-Abina, A. Kauskot, R. Elfeky, C. Rivat, S. Abbas, H. B. Gaspar, E. Macintyre, C. Picard, F. D. Bushman, A. Galy, A. Fischer, E. Six, A. J. Thrasher, M. Cavazzana

NATURE MEDICINE (2022)

Review Biochemistry & Molecular Biology

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan

Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Immunology

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Alan Kennedy, Erin Waters, Behzad Rowshanravan, Claudia Hinze, Cayman Williams, Daniel Janman, Thomas A. Fox, Claire Booth, Anne M. Pesenacker, Neil Halliday, Blagoje Soskic, Satdip Kaur, Omar S. Qureshi, Emma C. Morris, Shinji Ikemizu, Christopher Paluch, Jiandong Huo, Simon J. Davis, Emmanuel Boucrot, Lucy S. K. Walker, David M. Sansom

Summary: CD28 and CTLA-4 play important roles in regulating T cell immunity. The study found that CTLA-4 captures ligands through transendocytosis, and CD80 leads to ubiquitination and degradation of CTLA-4, while CD86 allows CTLA-4 to detach and recycle back to the cell surface. Clinically relevant mutations disrupt CD86 transendocytosis and are associated with autoimmune diseases.

NATURE IMMUNOLOGY (2022)

Article Cell Biology

Therapeutic gene editing of T cells to correct CTLA-4 insufficiency

Thomas Andrew Fox, Benjamin Christopher Houghton, Lina Petersone, Erin Waters, Natalie Mona Edner, Alex McKenna, Olivier Preham, Claudia Hinze, Cayman Williams, Adriana Silva de Albuquerque, Alan Kennedy, Anne Maria Pesenacker, Pietro Genovese, Lucy Sarah Kate Walker, Siobhan Oisin Burns, David Michael Sansom, Claire Booth, Emma Catherine Morris

Summary: A gene editing strategy was designed to insert the CTLA-4 cDNA into primary human T cells, restoring CTLA-4 expression and demonstrating the feasibility of using T cell gene therapy for CTLA-4 insufficiency.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Immunology

Metabolic dyshomeostasis induced by SARS-CoV-2 structural proteins reveals immunological insights into viral olfactory interactions

Mercedes Lachen-Montes, Naroa Mendizuri, Karina Ausin, Miriam Echaide, Ester Blanco, Luisa Chocarro, Maria de Toro, David Escors, Joaquin Fernandez-Irigoyen, Grazyna Kochan, Enrique Santamaria

Summary: One common symptom of COVID-19 is a sudden loss of smell, and the SARS-CoV-2 virus has been detected in the olfactory bulb. By studying the expression of SARS-CoV-2 structural proteins in mouse olfactory bulb cells, researchers have uncovered widespread metabolic remodeling and differential activation dynamics in immune pathways, providing insights into the mechanism behind olfactory inflammation observed in COVID-19 patients.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

Miriam Echaide, Ibone Labiano, Marina Delgado, Angela Fernandez de Lascoiti, Patricia Ochoa, Maider Garnica, Pablo Ramos, Luisa Chocarro, Leticia Fernandez, Hugo Arasanz, Ana Bocanegra, Ester Blanco, Sergio Pineiro-Hermida, Pilar Morente, Ruth Vera, Maria Alsina, David Escors, Grazyna Kochan

Summary: In this study, immune profiling was performed in healthy donors and oncologic patients infected with SARS-CoV-2, BNT162b2-vaccinated, and with previous COVID-19. The findings showed that vaccination induced poor cellular immunity towards the S protein in cancer patients, while natural infection targeted the M and S proteins. Memory T-cell expansion was only observed in vaccinated donors who had previously been diagnosed with COVID-19.

CANCERS (2022)

Review Biochemistry & Molecular Biology

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors

Ester Blanco, Luisa Chocarro, Leticia Fernandez-Rubio, Ana Bocanegra, Hugo Arasanz, Miriam Echaide, Maider Garnica, Sergio Pineiro-Hermida, Grazyna Kochan, David Escors

Summary: Immunotherapies based on immune checkpoint blockade have shown promising clinical outcomes but lack efficacy in most cancer patients. Intratumor delivery of monoclonal antibodies (mAbs) has emerged as a potential solution to reduce adverse events and improve treatment efficacy. Gene therapy vectors expressing mAbs inside tumors offer an attractive approach for local intratumor delivery. This expanding research subject will likely play a key role in future oncology.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Cutting-Edge CAR Engineering: Beyond T Cells

Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, Hugo Arasanz, Ana Bocanegra, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Pineiro-Hermida, Ruth Vera, Grazyna Kochan, David Escors

Summary: Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for cancer, particularly in hematological malignancies. However, its efficacy in solid tumors is limited due to the immunosuppressive tumor microenvironment (TME) that inactivates engineered T cells. Myeloid lineage (M) cells in the TME are highly immunosuppressive and interact with other immune cells, leading to immunosuppression and angiogenesis. CAR-M cell therapy has emerged as a potential immunotherapy strategy to enhance the efficacy, survival, persistence, and safety of CAR treatments in solid tumors. However, the mechanisms of CAR-M action and their impact on the TME are still poorly understood.

BIOMEDICINES (2022)

Review Biochemistry & Molecular Biology

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Hugo Arasanz, Luisa Chocarro, Leticia Fernandez-Rubio, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana Elsa Huerta, Maria Alsina, Ruth Vera, David Escors, Grazyna Kochan

Summary: Bispecific antibodies hold promise as a therapy for cancer, demonstrating the ability to simultaneously inhibit multiple proteins involved in cancer progression. In lung cancer treatment, their development has been particularly intense due to extensive knowledge of underlying molecular pathways, especially in oncogene-driven tumors. This review provides an overview of the current landscape of bispecific antibodies in lung cancer treatment and discusses potential future expansion of their role.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Oncology

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

Inigo Les, Mireia Martinez, Ines Perez-Francisco, Maria Cabero, Lucia Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Inaki Elejalde, Grazyna Kochan, David Escors

Summary: Immune-checkpoint inhibitors (ICIs) are widely used in cancer treatment, but they can cause immune-related adverse events (irAEs) in a significant number of patients. Predicting irAEs has become important for managing patients on ICIs. This review discusses biomarkers that have shown potential for predicting irAEs, including those already available for clinical use and those under investigation. Although these biomarkers have not been validated in prospective studies, there is growing evidence supporting their use for predicting and characterizing irAEs, which depend on factors such as the type of cancer, ICI agent, and affected organ. Further research is needed to understand the mechanisms of irAEs and to assess the predictive capacity of different biomarkers.

CANCERS (2023)

Article Biochemistry & Molecular Biology

Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

Ana Bocanegra, Gonzalo Fernandez-Hinojal, Daniel Ajona, Ester Blanco, Miren Zuazo, Maider Garnica, Luisa Chocarro, Elvira Alfaro-Arnedo, Sergio Pineiro-Hermida, Pilar Morente, Leticia Fernandez, Ana Remirez, Miriam Echaide, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Alejandra Roncero, Carolina Gotera, Alfonso Ventura, Nerea Recalde, Jose G. Pichel, Juan Jose Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan

Summary: Recent studies show that baseline functional immunity is crucial for the success of immune checkpoint blockade therapies. In this study, high-dimensional systemic immune profiling was performed on non-small-cell lung cancer patients undergoing PD-L1/PD-1 blockade immunotherapy. Responders had a higher diversity of myeloid phenotypes in their peripheral blood. A diversity index was defined as a potential biomarker of response. Fractalkine (FKN), a chemokine linked to immune chemotaxis and adhesion, was identified as a biomarker of response and correlated with myeloid cell diversity. FKN inhibited lung adenocarcinoma growth in both human and mouse models through the involvement of systemic effector NK cells and increased tumor immune infiltration. FKN also sensitized mouse lung cancer models resistant to anti-PD-1 treatment to immunotherapy, indicating its potential therapeutic use in combination with immunotherapy.

EMBO REPORTS (2023)

Article Endocrinology & Metabolism

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

Marta Redondo-Munoz, Francisco Javier Rodriguez-Baena, Paula Aldaz, Adria Caballe-Mestres, Veronica Moncho-Amor, Maddalen Otaegi-Ugartemendia, Estefania Carrasco-Garcia, Ana Olias-Arjona, Irene Lasheras-Otero, Eva Santamaria, Ana Bocanegra, Luisa Chocarro, Abby Grier, M. Monika Dzieciatkowska, Claudia Bigas, Josefina Martin, Uxue Urdiroz-Urricelqui, Florencio Marzo, Enrique Santamaria, Grazyna Kochan, David Escors, Ignacio Marcos Larrayoz, Holger Heyn, Angelo D'Alessandro, Camille Stephan-Otto Attolini, Ander Matheu, Claudia Wellbrock, Salvador Aznar Benitah, Berta Sanchez-Laorden, Imanol Arozarena

Summary: In this study, the anti-anginal drug ranolazine is found to sensitize BRAF inhibitor-resistant melanoma to targeted therapy and immunotherapy by rewiring fatty acid oxidation and the methionine salvage pathway. Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring.

NATURE METABOLISM (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Immunotherapy with an anti-PD-1 antibody expressed by a viral vector improves with agents reprogramming tumor associated myeloid cells

E. Blanco, N. Silva, L. Chocarro, H. Arasanz, A. Bocanegra, L. Fernandez, K. Ausin, J. Fernandez, E. Santamaria, M. Garnica, S. Pineiro, M. Echaide, P. Ramos, R. Vera, D. Escors, C. Smerdou, G. Kochan

HUMAN GENE THERAPY (2022)

Review Physics, Multidisciplinary

The Uncertainty Principle and the Minimal Space-Time Length Element

David Escors, Grazyna Kochan

Summary: Quantum gravity theories require a minimal measurable length, which contradicts the classical uncertainty principle and Lorentz invariance. The generalized uncertainty principle (GUP) from string theories and its modifications have been developed to address these incompatibilities. This has implications for space-time quantization.

PHYSICS (2022)

Meeting Abstract Oncology

Identification of a PD-1/LAG-3 co-expression profile in human tumor-infiltrating T cells uncovers a T cell dysfunctionality genetic regulated programme

L. Chocarro, E. Blanco, H. Arasanz, L. Fernandez-Rubio, A. I. Bocanegra, M. Echaide, M. Garnica, P. Ramos, S. Pineiro-Hermida, M. J. Garcia-Granda, R. Vera, E. Santamaria, J. Fernandez-Irigoyen, G. Kochan, D. Escors

ANNALS OF ONCOLOGY (2022)

暂无数据